0001209191-21-026292.txt : 20210409 0001209191-21-026292.hdr.sgml : 20210409 20210409175228 ACCESSION NUMBER: 0001209191-21-026292 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210407 FILED AS OF DATE: 20210409 DATE AS OF CHANGE: 20210409 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Morosini Deborah CENTRAL INDEX KEY: 0001824625 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39527 FILM NUMBER: 21818739 MAIL ADDRESS: STREET 1: C/O PRELUDE THERAPEUTICS INCORPORATED STREET 2: 200 POWDER MILL ROAD CITY: WILMINGTON STATE: DE ZIP: 19803 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Prelude Therapeutics Inc CENTRAL INDEX KEY: 0001678660 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 811384762 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 200 POWDER MILL ROAD CITY: WILMINGTON STATE: DE ZIP: 19803 BUSINESS PHONE: (302) 547-3768 MAIL ADDRESS: STREET 1: 200 POWDER MILL ROAD CITY: WILMINGTON STATE: DE ZIP: 19803 FORMER COMPANY: FORMER CONFORMED NAME: Prelude Therapeutics Inc. DATE OF NAME CHANGE: 20160630 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-04-07 0 0001678660 Prelude Therapeutics Inc PRLD 0001824625 Morosini Deborah C/O PRELUDE THERAPEUTICS INCORPORATED 200 POWDER MILL ROAD WILMINGTON DE 19803 0 1 0 0 EVP, Chief of Clinical Affairs Common Stock 2021-04-07 4 M 0 1000 1.89 A 1444 D Common Stock 2021-04-07 4 S 0 1000 40.043 D 444 D Employee Stock Option (right to buy) 1.89 2021-04-07 4 M 0 1000 0.00 D 2030-03-26 Common Stock 1000 7646 D The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. The stock option is fully vested. /s/ Brian Piper, Attorney-in-Fact 2021-04-09